Clinical trial
A Study of Guselkumab in Participants With Moderately to Severely Active…
NCT04033445 · Janssen Research & Development, LLC, Industry · Active, not recruiting
Key facts
| NCT number | NCT04033445 |
|---|---|
| Title | A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| Official title | A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| Acronym | QUASAR |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Placebo, Guselkumab |
| Enrollment | 1,064 |
| Start date | Sep 26, 2019 |
| Primary completion | Sep 19, 2023 |
| Completion | Sep 29, 2027 |
| First posted | Jul 26, 2019 |
| Last update posted | Feb 13, 2026 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hungary and 22 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: